



HHS Public Access

Author manuscript

Cancer Res. Author manuscript; available in PMC 2015 April 01.

Published in final edited form as:

Cancer Res. 2014 November 15; 74(22): 6731–6732. doi:10.1158/0008-5472.CAN-14-2966.

Retraction: Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig 2-Positive Glioma Tumor–Initiating Cells

The authors wish to retract the article entitled “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig 2-Positive Glioma Tumor–Initiating Cells,” which was published in the May 15, 2013 (73:3062) issue of *Cancer Research* (1).

A University of Texas MD Anderson Cancer Center internal investigation has found that Dr. Jun Fu committed research misconduct as defined by 42 CFR Part 93 and MD Anderson’s Research Misconduct Policy. Specifically, that Dr. Jun Fu falsified the data appearing in Figure 8B by modifying the death dates of mouse specimens to produce a fabricated survivability curve for GSC-11. Dr. Jun Fu has accepted full responsibility for this breach of research integrity. This constitutes a violation of MD Anderson policy concerning the ethical conduct of research, as well as a significant departure from the research practices commonly accepted by MD Anderson research community. Because of the severity of this breach of research integrity, the authors believe that retraction of the article represents the most appropriate course of action to ensure the accuracy of the scientific record.

The internal panel further concluded that none of the other co-authors of this article knew, or had reason to suspect that the data presented in the article had been manipulated by Dr. Jun Fu.

All co-authors have agreed to this retraction.

Dimpy Koul

Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center,
Houston, Texas

Jun Yao

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson
Cancer, Houston, Texas

Shuzhen Wang

Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center,
Houston, Texas

Ying Yuan

Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
Houston, Texas

Erik Sulman

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center,
Houston, Texas

Frederick Lang

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center,
Houston, Texas

W.K. Alfred Yung

Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center,
Houston, Texas

Howard Colman

Department of Neurosurgery, Huntsman Cancer Hospital, Salt Lake City, Utah

References

1. Fun J, Koul D, Yao J, Wang S, Yuen Y, Colman H, et al. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells. *Cancer Res.* 2013; 73:3062–74. [PubMed: 23492364]